Prof Simon Harrison speaks to ecancer in an online interview for the virtual ASH 2020 meeting about a phase I first in human study of AMG 701 - an anti-B-cell maturation antigen (BCMA) half-life extended bispecific T-cell engager molecule (BiTE) - in relapsed/refractory multiple myeloma..
Prof Harrison explains how the anti-BCMA BiTE technology works and the details of the patient population used in the study, before going. onto discuss the dose-escalation and adverse effects experienced including cytokine release syndrome.
Prof Harrison concludes by saying how exciting these findings are and notes that it will be interesting to see the results of combination approaches.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.